Talaris Therapeutics (TALS) Competitors

Talaris Therapeutics (NASDAQ:TALS) and Scholar Rock (NASDAQ:SRRK) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, community ranking, valuation and institutional ownership.

Is TALS or SRRK more profitable?

Talaris Therapeutics' return on equity of -39.93% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Talaris Therapeutics	N/A	-39.93%	-37.37%
Scholar Rock	N/A	-145.60%	-91.83%

Does the media prefer TALS or SRRK?

In the previous week, Scholar Rock had 4 more articles in the media than Talaris Therapeutics. MarketBeat recorded 4 mentions for Scholar Rock and 0 mentions for Talaris Therapeutics. Scholar Rock's average media sentiment score of 1.28 beat Talaris Therapeutics' score of 0.00 indicating that Scholar Rock is being referred to more favorably in the news media.

Company	Overall Sentiment
Talaris Therapeutics	Neutral
Scholar Rock	Positive

Which has preferable valuation and earnings, TALS or SRRK?

Talaris Therapeutics has higher earnings, but lower revenue than Scholar Rock. Scholar Rock is trading at a lower price-to-earnings ratio than Talaris Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Talaris Therapeutics	N/A	N/A	-$73.89M	-$1.79	-11.12
Scholar Rock	$33.19M	92.83	-$165.79M	-$2.53	-12.83

Do analysts rate TALS or SRRK?

Scholar Rock has a consensus target price of $42.67, suggesting a potential upside of 31.48%. Given Scholar Rock's stronger consensus rating and higher probable upside, analysts clearly believe Scholar Rock is more favorable than Talaris Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Talaris Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Scholar Rock	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	3.14

Which has more volatility and risk, TALS or SRRK?

Talaris Therapeutics has a beta of 2.18, meaning that its stock price is 118% more volatile than the S&P 500. Comparatively, Scholar Rock has a beta of 0.28, meaning that its stock price is 72% less volatile than the S&P 500.

Does the MarketBeat Community prefer TALS or SRRK?

Scholar Rock received 158 more outperform votes than Talaris Therapeutics when rated by MarketBeat users. Likewise, 66.54% of users gave Scholar Rock an outperform vote while only 48.15% of users gave Talaris Therapeutics an outperform vote.

Company	Underperform	Outperform
Talaris Therapeutics	Outperform Votes 13 48.15%	Underperform Votes 14 51.85%
Scholar Rock	Outperform Votes 171 66.54%	Underperform Votes 86 33.46%

Do insiders & institutionals believe in TALS or SRRK?

67.6% of Talaris Therapeutics shares are held by institutional investors. Comparatively, 91.1% of Scholar Rock shares are held by institutional investors. 16.5% of Talaris Therapeutics shares are held by insiders. Comparatively, 13.3% of Scholar Rock shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Scholar Rock beats Talaris Therapeutics on 10 of the 17 factors compared between the two stocks.